Dynavax Technologies Total Liabilities 2010-2022 | DVAX

Dynavax Technologies total liabilities from 2010 to 2022. Total liabilities can be defined as the total value of all possible claims against the corporation.
Dynavax Technologies Annual Total Liabilities
(Millions of US $)
2021 $817
2020 $295
2019 $271
2018 $148
2017 $19
2016 $20
2015 $30
2014 $38
2013 $18
2012 $25
2011 $34
2010 $32
2009 $44
Dynavax Technologies Quarterly Total Liabilities
(Millions of US $)
2022-03-31 $721
2021-12-31 $817
2021-09-30 $852
2021-06-30 $565
2021-03-31 $390
2020-12-31 $295
2020-09-30 $284
2020-06-30 $271
2020-03-31 $247
2019-12-31 $271
2019-09-30 $262
2019-06-30 $256
2019-03-31 $253
2018-12-31 $148
2018-09-30 $139
2018-06-30 $133
2018-03-31 $129
2017-12-31 $19
2017-09-30 $13
2017-06-30 $11
2017-03-31 $13
2016-12-31 $20
2016-09-30 $31
2016-06-30 $29
2016-03-31 $25
2015-12-31 $30
2015-09-30 $28
2015-06-30 $35
2015-03-31 $37
2014-12-31 $38
2014-09-30 $25
2014-06-30 $23
2014-03-31 $20
2013-12-31 $18
2013-09-30 $19
2013-06-30 $19
2013-03-31 $22
2012-12-31 $25
2012-09-30 $35
2012-06-30 $31
2012-03-31 $32
2011-12-31 $34
2011-09-30 $28
2011-06-30 $29
2011-03-31 $29
2010-12-31 $32
2010-09-30 $39
2010-06-30 $59
2010-03-31 $46
2009-12-31 $44
2009-09-30 $44
2009-06-30 $45
2009-03-31 $58
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.637B $0.439B
Dynavax Technologies discovers, develops, and intends to commercialize innovative products to treat and prevent allergies, infectious diseases, and chronic inflammatory diseases using versatile, proprietary approaches that alter immune system responses in highly specific ways. Dynavax's clinical development programs are based on immunostimulatory sequences which are short DNA sequences that enhance the ability of the immune system to fight disease and control chronic inflammation.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $163.597B 9.95
Bio-Rad Laboratories (BIO.B) United States $14.907B 32.33
QIAGEN (QGEN) Netherlands $10.865B 17.15
Biohaven Pharmaceutical Holding (BHVN) United States $10.248B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.228B 0.00
Arcus Biosciences (RCUS) United States $1.901B 48.18
Emergent Biosolutions (EBS) United States $1.599B 6.85
Myovant Sciences (MYOV) United Kingdom $1.236B 0.00
Zymeworks (ZYME) Canada $0.320B 0.00
Gelesis Holdings (GLS) United States $0.114B 0.00
Enzo Biochem (ENZ) United States $0.104B 0.00
Ambrx Biopharma (AMAM) United States $0.103B 0.00
SQZ Biotechnologies (SQZ) United States $0.087B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00